Imatinib Grindeks

Imatinib, the active ingredient in Imatinib Grindeks, is a tyrosine kinase inhibitor presented as an oral dosage form for oral use. It treats chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumor in adult patients. It is manufactured according to EU standards and is indicated for patients who have the relevant genetic markers.

GNH USA supplies Imatinib Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to Good Distribution Practice and provides regulatory documentation to support import and clinical use.

Imatinib provides targeted inhibition of tyrosine‑kinase driven malignancies, offering disease‑modifying therapy for several cancer types.

- Chronic myeloid leukemia (CML): blocks BCR‑ABL activity, leading to hematologic and cytogenetic remission. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): suppresses leukemic blast proliferation by inhibiting BCR‑ABL signaling. - Gastrointestinal stromal tumor (GIST): induces tumor shrinkage through inhibition of c‑KIT and PDGFR pathways.

Adverse reactions may occur during treatment with Imatinib Grindeks.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often in the lower extremities. - Muscle cramps or pain: intermittent skeletal discomfort. - Fatigue: generalized tiredness affecting daily activities.

Serious or Rare Side Effects: - Neutropenia or severe leukopenia: increased infection risk. - Hepatotoxicity: elevated liver enzymes or hepatic failure. - Cardiac failure or left‑ventricular dysfunction: signs of reduced cardiac output.

Clinicians should observe specific safety measures when prescribing Imatinib Grindeks.

- Monitor blood counts: perform regular complete blood count assessments. - Assess liver function: check hepatic enzymes before and during therapy. - Evaluate cardiac status: baseline and periodic echocardiograms for patients with cardiac history. - Avoid strong CYP3A4 inhibitors: drugs such as ketoconazole may raise plasma levels. - Use caution in renal impairment: dose adjustments may be required. - Store at ambient temperature: keep in the original container, protect from moisture.

Imatinib may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can increase imatinib exposure. - Azole antifungals (e.g., voriconazole): may raise plasma concentrations. - Macrolide antibiotics (e.g., clarithromycin): potentiate toxicity risk. - St. John’s wort: induces CYP3A4 and may reduce effectiveness.

Moderate Interactions (Monitor Closely): - Mild CYP3A4 inhibitors (e.g., diltiazem): may modestly increase levels. - Warfarin: monitor INR for potential anticoagulation changes. - Diuretics: watch for electrolyte disturbances, especially potassium.